Skip to main content

Advertisement

Table 2 The association of the gene expressions and pathological characteristics

From: A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

Characteristic No. of Patients APTX mRNA BRCA1 mRNA ERCC1 mRNA ISG15 mRNA Topo1 mRNA
   mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Age, y       
 ≥ 63 91 (52%) 4.81 ± 3.78 8.61 ± 5.73 15.28 ± 10.01 4.48 ± 3.69 8.03 ± 7.30
 < 63 84 (48%) 4.09 ± 3.76 7.90 ± 5.95 14.75 ± 9.28 5.79 ± 6.90 7.47 ± 5.81
Sex       
 Male 131 (75%) 4.77 ± 3.33 8.41 ± 5.57 15.74 ± 10.19 5.54 ± 5.62 7.95 ± 7.17
 Female 44 (25%) 3.58 ± 3.29 7.92 ± 6.67 12.77 ± 7.30 3.53 ± 4.27* 7.21 ± 4.62
Tumor Site       
 Distal stomach 62 (35%) 4.79 ± 2.87 8.97 ± 6.52 16.12 ± 10.36 7.05 ± 7.75 8.09 ± 5.93
 Proximal stomach 70 (40%) 4.16 ± 3.10 8.33 ± 5.72 13.97 ± 9.09 3.61 ± 2.64 7.40 ± 6.63
 Whole stomach 43 (25%) 4.60 ± 4.44 7.12 ± 4.74 15.31 ± 9.70 4.61 ± 3.43 7.06 ± 7.94
Stage       
 I 20 (11%) 4.25 ± 4.47 5.91 ± 3.40 13.40 ± 7.07 1.89 ± 0.83 5.89 ± 4.03
 II 41 (23%) 4.19 ± 3.01 8.58 ± 5.09 14.70 ± 9.56 6.76 ± 7.96 8.91 ± 6.35
 III 110 (63%) 4.66 ± 3.38 8.19 ± 5.75 15.56 ± 10.16 4.67 ± 4.01 7.70 ± 7.07
 IV 4 (3%) 4.20 ± 4.61 15.88 ± 17.90 11.01 ± 5.00 7.25 ± 6.33 4.03 ± 1.63
Histological grade       
 2 36 (21%) 5.05 ± 3.54* 10.97 ± 7.33 15.78 ± 9.52 4.86 ± 4.75 8.08 ± 6.61
 3 81 (46%) 3.92 ± 3.55 7.81 ± 5.16 14.30 ± 9.64 3.68 ± 2.75 7.18 ± 6.08
 Mixed 1–2 6 (3%) 3.63 ± 4.51 7.17 ± 2.13 15.17 ± 12.40 8.00 ± 8.94 8.42 ± 6.02
 Mixed 2–3 52 (30%) 4.55 ± 2.53 7.06 ± 5.27 15.65 ± 9.96 7.16 ± 7.74 8.44 ± 7.18
Lymph node metastasis       
 No 40 (23%) 4.58 ± 3.39 8.70 ± 5.08 14.68 ± 7.31 5.97 ± 8.17 7.48 ± 4.47
 Yes 135 (77%) 4.46 ± 3.35 8.16 ± 6.05 15.16 ± 10.33 4.78 ± 4.12 7.87 ± 7.23
  1. * P < 0.05.